Lumos Pharma Stock (NASDAQ:LUMO)
Previous Close
$4.32
52W Range
$1.37 - $4.58
50D Avg
$4.04
200D Avg
$2.99
Market Cap
$37.45M
Avg Vol (3M)
$90.78K
Beta
0.33
Div Yield
-
LUMO Company Profile
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.